Wexler, T. L., & Page‐Wilson, G. (2023). Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies. British Journal of Clinical Pharmacology, 89(4), 1304–1317. Portico. https://doi.org/10.1111/bcp.15660

Lyashchenko, A. K., Yu, Y., McMahon, D. J., Bies, R., Yin, M. T., & Cremers, S. (2022). Systemic exposure to hydroxychloroquine and its relationship with outcome in severely ill COVID‐19 patients in New York City. British Journal of Clinical Pharmacology, 89(1), 299–315. Portico. https://doi.org/10.1111/bcp.15489

Goyal, P., Safford, M. M., Hilmer, S. N., Steinman, M. A., Matlock, D. D., Maurer, M. S., Lachs, M. S., & Kronish, I. M. (2022). N‐of‐1 trials to facilitate evidence‐based deprescribing: Rationale and case study. British Journal of Clinical Pharmacology, 88(10), 4460–4473. Portico. https://doi.org/10.1111/bcp.15442

Ganapathi, M., Campbell, P., Ofori, K., Aggarwal, V., Francis, R. O., & Kratz, A. (2022). Impact of pre‐emptive rapid testing for glucose‐6‐phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study. British Journal of Clinical Pharmacology, 88(9), 4163–4170. Portico. https://doi.org/10.1111/bcp.15353

Arout, C. A., Haney, M., Herrmann, E. S., Bedi, G., & Cooper, Z. D. (2021). A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. British Journal of Clinical Pharmacology, 88(1), 347–355. Portico. https://doi.org/10.1111/bcp.14973